Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Trauner M, Bowlus CL, Gulamhusein A, Hameed B, Caldwell SH, Shiffman ML, Landis C, Muir AJ, Billin A, Xu J, Liu X, Lu X, Chung C, Myers RP, Kowdley KV. Trauner M, et al. Among authors: caldwell sh. Clin Gastroenterol Hepatol. 2023 Jun;21(6):1552-1560.e2. doi: 10.1016/j.cgh.2022.07.024. Epub 2022 Aug 4. Clin Gastroenterol Hepatol. 2023. PMID: 35934287 Clinical Trial.
Treating NAFLD: future prospects.
Caldwell SH, Kowdley KV. Caldwell SH, et al. J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S67-8. doi: 10.1097/01.mcg.0000168646.94282.e4. J Clin Gastroenterol. 2006. PMID: 16540771 No abstract available.
[No title available]
[No authors listed] [No authors listed] PMID: 16672829
Controversies in the Diagnosis and Management of NAFLD and NASH.
Rinella ME, Loomba R, Caldwell SH, Kowdley K, Charlton M, Tetri B, Harrison SA. Rinella ME, et al. Among authors: caldwell sh. Gastroenterol Hepatol (N Y). 2014 Apr;10(4):219-27. Gastroenterol Hepatol (N Y). 2014. PMID: 24976805 Free PMC article.
Practice patterns in NAFLD and NASH: real life differs from published guidelines.
Rinella ME, Lominadze Z, Loomba R, Charlton M, Neuschwander-Tetri BA, Caldwell SH, Kowdley K, Harrison SA. Rinella ME, et al. Among authors: caldwell sh. Therap Adv Gastroenterol. 2016 Jan;9(1):4-12. doi: 10.1177/1756283X15611581. Therap Adv Gastroenterol. 2016. PMID: 26770262 Free PMC article.
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR; GS-US-384-1497 Investigators. Loomba R, et al. Among authors: caldwell sh. Hepatology. 2018 Feb;67(2):549-559. doi: 10.1002/hep.29514. Epub 2017 Dec 26. Hepatology. 2018. PMID: 28892558 Free PMC article. Clinical Trial.
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K. Younossi ZM, et al. Among authors: caldwell sh. Hepatology. 2018 Jul;68(1):361-371. doi: 10.1002/hep.29724. Hepatology. 2018. PMID: 29222911 Free PMC article.
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K. Younossi ZM, et al. Among authors: caldwell sh. Hepatology. 2018 Jul;68(1):349-360. doi: 10.1002/hep.29721. Hepatology. 2018. PMID: 29222917 Free PMC article.
296 results